Poly-DL-Lactic-co-Glycolic Acid | Pharma Excipients | News | Suppliers

Suanfarma, at the Core of a Better Life.

Virtual Booth

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

INACTIVE PHARMA INGREDIENTS

13 Suppliers, 12 USDMF, 1 Listed Suppliers, 3 VMF, 8 Listed Suppliers

13 Suppliers
12 USDMF
1 Listed Suppliers
3 VMF
8 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers Suppliers

1 FDF Dossiers Suppliers

EXCIPIENTS BY APPLICATIONS

7 Parenteral, 2 Controlled & Modified Release

7 Parenteral
2 Controlled & Modified Release

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

1 DATA COMPILATION #PharmaFlow

MARKET PLACE

5 EXCIPIENTS

5 EXCIPIENTS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Poly dl lactic co glycolic acid , 50:50; 12000 mw

Poly lactic-co-glycolic acid (PLGA) is biocompatible & biodegradable polymer which is used to fabricate devices for drug delivery & tissue engineering applications.

SUPPLIERS

01

Evonik

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IPPE

Attending

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Contact Supplier

Germany

Virtual Booth

Digital Content

USDMF

Click Us!

CEP/COS JDMF EU-WC NDC KDMF VMF

Others AUDIT

Product Web Link

02

PCAS

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Contact Supplier

France

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

PCAS

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

Contact Supplier

France

Virtual Booth

Digital Content

USDMF

CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Mitsui & Co.,Ltd

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

05

Mitsui & Co.,Ltd

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

06

Diqi Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

07

Diqi Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

08

Diqi Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

09

Diqi Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

10

Diqi Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat

Not Confirmed

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

Reset Filter

Ask Us

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Polylactide

China

Duphat

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

VMF

Reset Filter

Ask Us

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FINISHED DOSAGE FORMULATIONS

Upload your portfolio for free, ask us

FDF DOSSIERS SUPPLIERS

01

RECORDATI RARE

PASIREOTIDE PAMOATE

Duphat

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EXCIPIENTS BY APPLICATIONS

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

01

Seqens

France

Duphat

Not Confirmed

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Dosage Form : Injectable / Parenteral

Grade : Parenteral

Category : Parenteral

Brand Name : Expansorb® PLGA / PEG

Application : Parenteral

Excipient Details : Expansorb® PLGA? / PEG copolymers are used as functional excipients in single dose injections for controlled and slow drug release (weeks to months).

Pharmacopoeia Ref : N/A

Technical Specs : Classic and ultrapure LMP

Ingredient(s) : Poly-DL-Lactic-co-Glycolic Acid

02

Nanjing Well Pharmaceutical

China

Duphat

Not Confirmed

Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Dosage Form : Injectable / Parenteral

Grade : Parenteral

Category : Parenteral

Brand Name : Polylactide-co-glycolide (75:25)

Application : Parenteral

Excipient Details : Poly (lactide-co-glycolide) (75:25) is used as a carrier material for sustained-release formulations including microspheres, nanocapsules & gels.

Pharmacopoeia Ref : ChP/USP

Technical Specs : Polylactide-co-glycolide (75:25); Intrinsic Viscosity: 20-30 mL/g...

Ingredient(s) : PLGA Polymers

Nanjing Well Polylactide-co-glycolide (75:25)

03

Seqens

France

Duphat

Not Confirmed

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Dosage Form : Injectable / Parenteral

Grade : Parenteral

Category : Parenteral

Brand Name : Expansorb® PLGA

Application : Parenteral

Excipient Details : Expansorb® PLGA copolymers are used as functional excipients for slow and controlled drug release (weeks to months) with a single injection.

Pharmacopoeia Ref : NA

Technical Specs : Classic and ultrapure LMP

Ingredient(s) : Poly-DL-Lactic-co-Glycolic Acid

04

Nanjing Well Pharmaceutical

China

Duphat

Not Confirmed

Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Dosage Form : Injectable / Parenteral

Grade : Parenteral

Category : Parenteral

Brand Name : Polylactide-co-glycolide (50:50)

Application : Parenteral

Excipient Details : Poly(lactide-co-glycolide) (50:50) is a biodegradable carrier used in parenteral dosage forms. It is also used to develop controlled release products.

Pharmacopoeia Ref : ChP/USP

Technical Specs : Polylactide-co-glycolide (50:50); Intrinsic Viscosity: 15-25 mL/g...

Ingredient(s) : PLGA Polymers

Nanjing Well Polylactide-co-glycolide (50:50)

05

Seqens

France

Duphat

Not Confirmed

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Dosage Form : Injectable / Parenteral

Grade : Parenteral

Category : Parenteral

Brand Name : Expansorb® PLGA 55:45-Glu

Application : Parenteral

Excipient Details : Expansorb® PLGA 55:45-Glu is lactic acid & glycolic acid copolymer used as functional excipients in injectables for slow and controlled drug release.

Pharmacopoeia Ref : NA

Technical Specs : Classic and ultrapure LMP

Ingredient(s) : Poly-DL-Lactic-co-Glycolic Acid

06

Nanjing Well Pharmaceutical

China

Duphat

Not Confirmed

Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Dosage Form : Injectable / Parenteral

Grade : Parenteral

Category : Parenteral

Brand Name : Polylactide-co-glycolide (85:15)

Application : Parenteral

Excipient Details : Poly (lactide-co-glycolide) (85:15) is a biodegradable carrier used in parenteral controlled release dosage forms such as microspheres & nanocapsules.

Pharmacopoeia Ref : ChP/USP

Technical Specs : Polylactide-co-glycolide (85:15); Intrinsic Viscosity: 15-25 mL/g...

Ingredient(s) : PLGA Polymers

Nanjing Well Polylactide-co-glycolide (85:15)

07

Nomisma Healthcare

India

Duphat

Not Confirmed

Controlled Modified Release

01

02

Nomisma Healthcare

India

Duphat

Not Confirmed

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards. Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio. Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients. The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.